Peanut Allergy Competitive Landscape Report 2018 - Market Insights, Epidemiology and Market Forecast to 2025 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 3, 2018--The “Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025 provides comprehensive insights on the therapeutics development and the global market trends for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The report covers the therapeutics market revenue, treatment practice and Peanut Allergy forecasted market share from 2017 to 2025, along with the global epidemiological forecast for this indication.
The reported prevalent cases of Peanut Allergy in 2015 were 6,719,025 in 7MM and estimated to increase in coming years. In certain European countries prevalence will decrease owing to the overall decrease in population. Currently there is no effective therapeutics or prophylactic products are available in market. The historical and current market size for this allergy comprises of Epinephrine and Anti-histamines. The first entry of Peanut Allergy treatment is expected in 2019 in US.
The report also includes therapeutic competitive landscape including 15+ pipeline products in this space. It further provides comparative pipeline analysis at various stages covering Phase III, Phase II, Phase I, Pre-clinical and Discovery. Active pipeline therapeutics assessment by stage, therapy type, route of administration and molecule type is also provided. Additionally, it also features the dormant and discontinued pipeline products. Leading companies in this space are Aimmune, DBV Technologies and AnaptysBio.
Key Topics Covered:Peanut Allergy - Overview Peanut Allergens Symptoms Clinical Symptoms Risk Factors Causes Test and Diagnosis Peanut Allergy Management and Treatment Being prepared for a reaction Prevalence Scientific Research Experimental Approaches Sensitization To Do/Not to Do Epidemiology Overview - 7MM, 2015-2025 Comparative Analysis Product Type Late Stage Products (Phase III) AR101: Aimmune Therapeutics ANB020: AnaptysBio SAR-439794: Sanofi SVP-CPE + SVP-Resiquimod: Selecta Biosciences Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant and Discontinued Products Comparative Analysis Market Assessment: 7MM Appendix
Companies MentionedAimmune Allergy Therapeutics AnaptysBio ASIT biotech BioLingus DBV Technologies Genentech Laboratorios LETI Prota Therapeutics Selecta Biosciences Virtici
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fzflbs/peanut_allergy?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181203005354/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Allergy Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/03/2018 04:53 AM/DISC: 12/03/2018 04:53 AM